Skip to main content
. 2020 Oct 12;2(1):100107. doi: 10.1016/j.jtocrr.2020.100107

Figure 2.

Figure 2

Forest plot of HR for (A) PFS and (B) OS of patients with NSCLC receiving the combination of gefitinib and platinum-based chemotherapy (carboplatin plus pemetrexed) versus gefitinib monotherapy. CBDCA, carboplatin; CI, confidence interval; HR, hazard ratio; OS, overall survival; PEM, pemetrexed; PFS, progression-free survival.